NurExone Biologic Inc.
NRX.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.78% | 20.64% | -10.01% | -8.54% | -23.68% |
| Total Depreciation and Amortization | 12.77% | 11.90% | -2.33% | 10.26% | 116.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.73% | 5.11% | 0.00% | -6.01% | 5.38% |
| Change in Net Operating Assets | 1.03% | -145.99% | 26.19% | 159.89% | -672.45% |
| Cash from Operations | 8.57% | -20.34% | -8.22% | 43.17% | -112.10% |
| Capital Expenditure | 25.00% | -500.00% | 93.75% | 30.43% | 84.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 25.00% | -500.00% | 93.75% | 28.89% | 85.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -25.00% | -700.00% | 66.67% | 57.14% | 12.50% |
| Issuance of Common Stock | 113.27% | -32.75% | 74.26% | -37.47% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -197.33% |
| Cash from Financing | 113.94% | -33.21% | 74.73% | 414.12% | -85.94% |
| Foreign Exchange rate Adjustments | 700.00% | -109.24% | 3,075.00% | 98.18% | -10,900.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 571.43% | -138.28% | 671.43% | 93.86% | -1,421.01% |